Colorectal cancer care in elderly patients: Unsolved issues

Digestive and Liver Disease

Volumn 48, Issue 10, 2016, Pages 1112-1118

  Aparicio, Thomas ^a   Pamoukdjian, Frederic ^a   Quero, Laurent ^b   Manfredi, Sylvain ^c   Wind, Philippe ^a   Paillaud, Elena ^d  

^a AVICENNE HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d HENRI MONDOR HOSPITAL   (France)

Author keywords

Adjuvant therapy; Chemotherapy; Geriatric oncology; Radiotherapy; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR ANTIBODY; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR;

ADJUVANT CHEMOTHERAPY; AGED; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; GERIATRIC ASSESSMENT; HUMAN; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; MASS SCREENING; MOLECULARLY TARGETED THERAPY; PROCEDURES; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; GERIATRIC ASSESSMENT; HUMANS; MASS SCREENING; MOLECULAR TARGETED THERAPY; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84973902135     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2016.05.011     Document Type: Review

References (84)

1. [1] Frerot, M., Jooste, V., Binquet, C., et al. Factors influencing inclusion in digestive cancer clinical trials: a population-based study. Digestive and Liver Disease 47 (2015), 891–896.
2. [2] Sorbye, H., Pfeiffer, P., Cavalli-Bjorkman, N., et al. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer 115 (2009), 4679–4687.
3. [3] Yee, K.W., Pater, J.L., Pho, L., et al. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier?. Journal of Clinical Oncology 21 (2003), 1618–1623.
4. [4] Papamichael, D., Audisio, R.A., Glimelius, B., et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Annals of Oncology 26 (2015), 463–476.
5. [5] Vercelli, M., Capocaccia, R., Quaglia, A., et al. Relative survival in elderly European cancer patients: evidence for health care inequalities. The EUROCARE Working Group. Critical Reviews in Oncology/Hematology 35 (2000), 161–179.
6. [6] Surgery for colorectal cancer in elderly patients: a systematic review. Colorectal Cancer Collaborative Group. Lancet 356 (2000), 968–974.
7. [7] Ferrat, E., Paillaud, E., Laurent, M., et al. Predictors of 1-year mortality in a prospective cohort of elderly patients with cancer. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 70 (2015), 1148–1155.
8. [8] Hurria, A., Togawa, K., Mohile, S.G., et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. Journal of Clinical Oncology 29 (2011), 3457–3465.
9. [9] Soubeyran, P., Fonck, M., Blanc-Bisson, C., et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. Journal of Clinical Oncology 30 (2012), 1829–1834.
10. [10] Balducci, L., Extermann, M., Management of cancer in the older person: a practical approach. Oncologist 5 (2000), 224–237.
11. [11] Aparicio, T., Navazesh, A., Boutron, I., et al. Half of elderly patients routinely treated for colorectal cancer receive a sub-standard treatment. Critical Reviews in Oncology/Hematology 71 (2009), 249–257.
12. [12] Doat, S., Thiebaut, A., Samson, S., et al. Elderly patients with colorectal cancer: treatment modalities and survival in France. National data from the ThInDiT cohort study. European Journal of Cancer 50 (2014), 1276–1283.
13. [13] Aparicio, T., Bouarioua, N., Lobry, C., Evolution de la prescription d'une chimiothérapie adjuvante pour cancer du côlon après 75ans sur la période 1995–2005. Journal Oncogériatrie 6 (2015), 13–16.
14. [14] Mahoney, T., Kuo, Y.H., Topilow, A., et al. Stage III colon cancers: why adjuvant chemotherapy is not offered to elderly patients. Archives of Surgery 135 (2000), 182–185.
15. [15] Extermann, M., Albrand, G., Chen, H., et al. Are older French patients as willing as older American patients to undertake chemotherapy?. Journal of Clinical Oncology 21 (2003), 3214–3219.
16. [16] Puts, M.T., Hardt, J., Monette, J., et al. Use of geriatric assessment for older adults in the oncology setting: a systematic review. Journal of the National Cancer Institute 104 (2012), 1133–1163.
17. [17] Kenis, C., Bron, D., Libert, Y., et al. Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study. Annals of Oncology 24 (2013), 1306–1312.
18. [18] Caillet, P., Canoui-Poitrine, F., Vouriot, J., et al. Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study. Journal of Clinical Oncology 29 (2011), 3636–3642.
19. [19] Brugel, L., Laurent, M., Caillet, P., et al. Impact of comprehensive geriatric assessment on survival, function, and nutritional status in elderly patients with head and neck cancer: protocol for a multicentre randomized controlled trial (EGeSOR). BMC Cancer, 14, 2014, 427.
20. [20] Kalsi, T., Babic-Illman, G., Ross, P.J., et al. The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people. British Journal of Cancer 112 (2015), 1435–1444.
21. [21] Hamaker, M.E., Jonker, J.M., de Rooij, S.E., et al. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncology 13 (2012), e437–e444.
22. [22] Handforth, C., Clegg, A., Young, C., et al. The prevalence and outcomes of frailty in older cancer patients: a systematic review. Annals of Oncology 26 (2015), 1091–1101.
23. [23] Bellera, C.A., Rainfray, M., Mathoulin-Pelissier, S., et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Annals of Oncology 23 (2012), 2166–2172.
24. [24] Liuu, E., Canoui-Poitrine, F., Tournigand, C., et al. Accuracy of the G-8 geriatric-oncology screening tool for identifying vulnerable elderly patients with cancer according to tumour site: the ELCAPA-02 study. Journal of Geriatric Oncology 5 (2014), 11–19.
25. [25] Paillaud, E., Liuu, E., Laurent, M., et al. Geriatric syndromes increased the nutritional risk in elderly cancer patients independently from tumour site and metastatic status. The ELCAPA-05 cohort study. Clinical Nutrition 33 (2014), 330–335.
26. [26] Faivre, J., Dancourt, V., Lejeune, C., et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 126 (2004), 1674–1680.
27. [27] Quarini, C., Gosney, M., Review of the evidence for a colorectal cancer screening programme in elderly people. Age and Ageing 38 (2009), 503–508.
28. [28] Arora, A., Singh, P., Colonoscopy in patients 80 years of age and older is safe, with high success rate and diagnostic yield. Gastrointestinal Endoscopy 60 (2004), 408–413.
29. [29] Day, L.W., Walter, L.C., Velayos, F., Colorectal cancer screening and surveillance in the elderly patient. American Journal of Gastroenterology 106 (2011), 1197–1206.
30. [30] Gross, C.P., McAvay, G.J., Krumholz, H.M., et al. The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Annals of Internal Medicine 145 (2006), 646–653.
31. [31] van Hees, F., Saini, S.D., Lansdorp-Vogelaar, I., et al. Personalizing colonoscopy screening for elderly individuals based on screening history, cancer risk, and comorbidity status could increase cost effectiveness. Gastroenterology, 2015.
32. [32] Lin, O.S., Kozarek, R.A., Schembre, D.B., et al. Screening colonoscopy in very elderly patients: prevalence of neoplasia and estimated impact on life expectancy. JAMA 295 (2006), 2357–2365.
33. [33] Faivre-Finn, C., Bouvier-Benhamiche, A.M., Phelip, J.M., et al. Colon cancer in France: evidence for improvement in management and survival. Gut 51 (2002), 60–64.
34. [34] Mitry, E., Bouvier, A.M., Esteve, J., et al. Benefit of operative mortality reduction on colorectal cancer survival. British Journal of Surgery 89 (2002), 1557–1562.
35. [35] Modini, C., Romagnoli, F., De Milito, R., et al. Octogenarians: an increasing challenge for acute care and colorectal surgeons. An outcomes analysis of emergency colorectal surgery in the elderly. Colorectal Disease 14 (2012), e312–e318.
36. [36] Lemmens, V.E., Janssen-Heijnen, M.L., Verheij, C.D., et al. Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer. British Journal of Surgery 92 (2005), 615–623.
37. [37] Allardyce, R.A., Bagshaw, P.F., Frampton, C.M., et al. Australasian Laparoscopic Colon Cancer Study shows that elderly patients may benefit from lower postoperative complication rates following laparoscopic versus open resection. British Journal of Surgery 97 (2010), 86–91.
38. [38] Kvasnovsky, C.L., Adams, K., Sideris, M., et al. Elderly patients have more infectious complications following laparoscopic colorectal cancer surgery. Colorectal Disease 18 (2016), 94–100.
39. [39] Finlayson, E., Zhao, S., Boscardin, W.J., et al. Functional status after colon cancer surgery in elderly nursing home residents. Journal of the American Geriatrics Society 60 (2012), 967–973.
40. [40] Mazzoni, G., Tocchi, A., Miccini, M., et al. Surgical treatment of liver metastases from colorectal cancer in elderly patients. International Journal of Colorectal Disease 22 (2007), 77–83.
41. [41] de Liguori, C.N., van Leeuwen, B.L., Ghaneh, P., et al. Liver resection for colorectal liver metastases in older patients. Critical Reviews in Oncology/Hematology 67 (2008), 273–278.
42. [42] Barrier, A., Ferro, L., Houry, S., et al. Rectal cancer surgery in patients more than 80 years of age. American Journal of Surgery 185 (2003), 54–57.
43. [43] Rutten H, den Dulk, M., Lemmens, V., et al. Survival of elderly rectal cancer patients not improved: analysis of population based data on the impact of TME surgery. European Journal of Cancer 43 (2007), 2295–2300.
44. [44] Manceau, G., Karoui, M., Werner, A., et al. Comparative outcomes of rectal cancer surgery between elderly and non-elderly patients: a systematic review. Lancet Oncology 13 (2012), e525–e536.
45. [45] Tougeron, D., Roullet, B., Paillot, B., et al. Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: results from two French tertiary centres. Digestive and Liver Disease 44 (2012), 350–354.
46. [46] Olsson, L.I., Granstrom, F., Glimelius, B., Socioeconomic inequalities in the use of radiotherapy for rectal cancer: a nationwide study. European Journal of Cancer 47 (2011), 347–353.
47. [47] Jung, B., Pahlman, L., Johansson, R., et al. Rectal cancer treatment and outcome in the elderly: an audit based on the Swedish Rectal Cancer Registry 1995–2004. BMC Cancer, 9, 2009, 68.
48. [48] Martijn, H., Vulto, J.C., Should radiotherapy be avoided or delivered differently in elderly patients with rectal cancer?. European Journal of Cancer 43 (2007), 2301–2306.
49. [49] Maas, M., Beets-Tan, R.G., Lambregts, D.M., et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. Journal of Clinical Oncology 29 (2011), 4633–4640.
50. [50] Faivre-Finn, C., Bouvier, A.M., Mitry, E., et al. Chemotherapy for colon cancer in a well-defined French population: is it under- or over-prescribed?. Alimentary Pharmacology and Therapeutics 16 (2002), 353–359.
51. [51] Lievre, A., Laurent, V., Cudennec, T., et al. Management of patients over 80 years of age treated with resection for localised colon cancer: results from a French referral centre. Digestive and Liver Disease 46 (2014), 838–845.
52. [52] Bouvier, A.M., Launoy, G., Lepage, C., et al. Trends in the management and survival of digestive tract cancers among patients aged over 80 years. Alimentary Pharmacology and Therapeutics 22 (2005), 233–241.
53. [53] Sargent, D.J., Goldberg, R.M., Jacobson, S.D., et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. New England Journal of Medicine 345 (2001), 1091–1097.
54. [54] Andre, T., Boni, C., Mounedji-Boudiaf, L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New England Journal of Medicine 350 (2004), 2343–2351.
55. [55] McCleary, N.J., Meyerhardt, J.A., Green, E., et al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. Journal of Clinical Oncology 31 (2013), 2600–2606.
56. [56] Tournigand, C., Andre, T., Bonnetain, F., et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. Journal of Clinical Oncology 30 (2012), 3353–3360.
57. [57] Aparicio, T., Francois, E., Cristol-Dalstein, L., et al. PRODIGE 34 – FFCD 1402 – ADAGE: adjuvant chemotherapy in elderly patients with resected stage III colon cancer. A randomized phase 3 trial. Digestive and Liver Disease 48 (2016), 206–207.
58. [58] Quasar Collaborative Group, Gray, R., Barnwell, J., et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomized study. Lancet 370 (2007), 2020–2029.
59. [59] O'Connor, E.S., Greenblatt, D.Y., LoConte, N.K., et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. Journal of Clinical Oncology 29 (2011), 3381–3388.
60. [60] Ribic, C.M., Sargent, D.J., Moore, M.J., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. New England Journal of Medicine 349 (2003), 247–257.
61. [61] Sargent, D.J., Marsoni, S., Monges, G., et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. Journal of Clinical Oncology 28 (2010), 3219–3226.
62. [62] Aparicio, T., Schischmanoff, O., Poupardin, C., et al. High prevalence of deficient mismatch repair phenotype and the V600E BRAF mutation in elderly patients with colorectal cancer. Journal of Geriatric Oncology 5 (2014), 384–388.
63. [63] Aparicio, T., Schischmanoff, O., Poupardin, C., et al. Deficient mismatch repair phenotype is a prognostic factor for colorectal cancer in elderly patients. Digestive and Liver Disease 45 (2013), 245–250.
64. [64] Folprecht, G., Cunningham, D., Ross, P., et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Annals of Oncology 15 (2004), 1330–1338.
65. [65] Folprecht, G., Seymour, M.T., Saltz, L., et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. Journal of Clinical Oncology 26 (2008), 1443–1451.
66. [66] Goldberg, R.M., Tabah-Fisch, I., Bleiberg, H., et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. Journal of Clinical Oncology 24 (2006), 4085–4091.
67. [67] Seymour, M.T., Thompson, L.C., Wasan, H.S., et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomized factorial trial. Lancet 377 (2011), 1749–1759.
68. [68] Aparicio, T., Lavau-Denes, S., Phelip, J.M., et al. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). Annals of Oncology 27 (2016), 121–127.
69. [69] Landre, T., Uzzan, B., Nicolas, P., et al. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. A meta-analysis. International Journal of Colorectal Disease 30 (2015), 1305–1310.
70. [70] Aparicio, T., Jouve, J.L., Teillet, L., et al. Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. Journal of Clinical Oncology 31 (2013), 1464–1470.
71. [71] Kozloff, M., Yood, M.U., Berlin, J., et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 14 (2009), 862–870.
72. [72] Cassidy, J., Saltz, L.B., Giantonio, B.J., et al. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. Journal of Cancer Research and Clinical Oncology 136 (2010), 737–743.
73. [73] Price, T.J., Zannino, D., Wilson, K., et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomized controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Annals of Oncology 23 (2012), 1531–1536.
74. [74] Cunningham, D., Lang, I., Marcuello, E., et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomized phase 3 trial. Lancet Oncology 14 (2013), 1077–1085.
75. [75] Aparicio, T., Bouche, O., Francois, E., et al. PRODIGE 20: bevacizumab+chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC) – a randomized phase II trial. Journal of Clinical Oncology, 33, 2015.
76. [76] Rosati, G., Aprile, G., Cardellino, G.G., et al. A review and assessment of currently available data of the EGFR antibodies in elderly patients with metastatic colorectal cancer. Journal of Geriatric Oncology 7 (2016), 134–141.
77. [77] Fornaro, L., Baldi, G.G., Masi, G., et al. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status. Critical Reviews in Oncology/Hematology 78 (2011), 243–251.
78. [78] Jehn, C.F., Boning, L., Kroning, H., et al. Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer. European Journal of Cancer 50 (2014), 1269–1275.
79. [79] Folprecht, G., Köhne, C., Bokemeyer, C., et al. Cetuximab and 1st-line chemotherapy in elderly and younger patients with metastatic colorectal cancer: a pooled analysis of the CRISTAL and OPUS studies. Annals of Oncology [European Cancer Congress], A597, 2010.
80. [80] Van Cutsem, E., Peeters, M., Siena, S., et al. A phase III randomized controlled trial of panitumumab (Pmab) in patients (pts) with metastatic colorectal cancer (mCRC): subset analyses in elderly pts and in pts with poor performance status. Proceedings of ASCO GI Cancer Symposium, vol. A349, 2007.
81. [81] Sastre, J., Aranda, E., Gravalos, C., et al. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Critical Reviews in Oncology/Hematology 77 (2011), 78–84.
82. [82] Sastre, J., Gravalos, C., Rivera, F., et al. First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study. Oncologist 17 (2012), 339–345.
83. [83] Sastre, J., Massuti, B., Pulido, G., et al. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. European Journal of Cancer 51 (2015), 1371–1380.
84. [84] Van Cutsem, E., Sobrero, A., Siena, S., et al. Regorafenib in progressive metastatic colorectal cancer: analysis of age subgroups in the phase III CORRECT trial. Journal of Clinical Oncology, 31(Suppl.), 2013.